**Biodesix Corporate Backgrounder**

Founded: 2006

Business Objective: Biodesix was founded in 2006 to develop diagnostic tests that address important clinical questions. By combining simple blood draws and a multi-omic approach with the power of artificial intelligence, Biodesix provides the most information available to fight cancer, quickly and accurately. In 2016, the company focused its commercialization efforts to provide solutions that concentrate on the continuum of lung cancer patient care from early diagnosis of lung nodules through late stage cancer. The company also partners with the world’s leading biotechnology and pharmaceutical companies to develop companion diagnostics. Biodesix acquired Integrated Diagnostics, Inc. in 2018, expanding its commercially available blood-based lung cancer tests to support more informed treatment decisions.

Products: The VeriStrat® proteomic test has been commercially available to the U.S. market since 2009 and the GeneStrat® genomic test has been available since 2015. The Biodesix Lung Reflex® testing strategy became commercially available in 2016, combining both VeriStrat and GeneStrat test results to support diagnostic and treatment guidance decisions for non-small cell lung cancer (NSCLC) patients in 72 hours. The BDX-XL2 test is designed to improve the management of patients with potentially malignant lung nodules and will be available to the U.S. market in the second half of 2019.

Pipeline: The BDX-012 test, a blood-based proteomic classifier is designed to identify patients who are not likely to benefit from anti-PD-1 monotherapy, but who may be considered for alternative treatment strategies including combination therapies.

Media Resources:

David Brunel, CEO

Scott Hutton, COO

Robin Harper Cowie, CFO

Bobbi Coffin, CMO

Media Contact:

Kena Hudson for Biodesix

510.908.0966

Kena@HudBio.com